SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001884552-24-000001
Filing Date
2024-02-12
Accepted
2024-02-12 10:19:46
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 12656
  Complete submission text file 0001884552-24-000001.txt   14469
Mailing Address 4660 LAJOLLA VILLAGE DRIVE SUITE 100 SAN DIEGO CA 92122
Business Address 4660 LAJOLLA VILLAGE DRIVE SUITE 100 SAN DIEGO CA 92122 650-800-3717
REVELATION BIOSCIENCES, INC. (Subject) CIK: 0001810560 (see all company filings)

IRS No.: 843898466 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91762 | Film No.: 24617888
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2-4 RUE EUGENE RUPPERT LUXEMBOURG N4 L-2453
Business Address 2-4 RUE EUGENE RUPPERT LUXEMBOURG N4 L-2453 352 621 233 175
AXA IM Prime Impact Master Fund I SCA SICAV-RAIF (Filed by) CIK: 0001884552 (see all company filings)

IRS No.: 000000000 | State of Incorp.: N4 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A